The Her2 Elisa Kits Market is expanding alongside the growing adoption of personalized medicine and biomarker-based cancer care. The global market is expected to increase from USD 800 million in 2025 to USD 1.2 billion by 2035, registering a 4.4% CAGR during the forecast period.

The increasing incidence of HER2-positive cancers is an important factor supporting demand for testing technologies. As clinicians place greater emphasis on identifying relevant biomarkers, laboratories require diagnostic tools capable of delivering consistent and informative measurements. This has strengthened interest in HER2 ELISA products across clinical and research environments.

The market is segmented by application into diagnostic, research, and therapeutic uses. Diagnostic applications hold the largest share, while research applications are supported by continued investigation into HER2 expression across different cancer types and the development of targeted therapies.

Product development is another important market trend. Ready-to-use, concentrated, and multiplex kits address different laboratory requirements, while colorimetric, fluorescent, and chemiluminescent detection methods provide options for different testing workflows. The expansion of these product categories gives suppliers opportunities to serve both routine laboratories and specialized research facilities.

Artificial intelligence and machine learning are emerging as additional opportunities for the sector. Their integration into diagnostic workflows may support data interpretation, laboratory efficiency, and more advanced analytical approaches. Partnerships between biotechnology, diagnostics, and research organizations are also expected to contribute to future product development.